| Literature DB >> 30986936 |
Hock Eng Khoo1,2, Hui Suan Ng3, Wai-Sum Yap4, Henri Ji Hang Goh5, Hip Seng Yim6.
Abstract
The risk of macular degeneration can be reduced through the consumption of antioxidant-rich foods, supplements, and nutraceutical formulas. This review focuses on the antioxidants, vitamins, and minerals that have been reported for reducing the risk of macular degeneration and other eye-related diseases. Antioxidants including anthocyanins, carotenoids, flavonoids, and vitamins have been shown to reduce the risk of eye-related diseases. Anthocyanins extracted from berries are powerful antioxidants. Cyanidin, delphinidin, malvidin, pelargonidin, peonidin, and petunidin are anthocyanin aglycones detected in berries, currants, and other colored fruits and vegetables. β-Carotene, as well as xanthophyll lutein and zeaxanthin, have been reported to reduce the risk of macular degeneration. Flavonoids from plants help in the prevention of eye-related diseases through anti-inflammatory mechanisms. A combination of these antioxidants, vitamins, and minerals possess a synergistic effect on the prevention or risk reduction of macular degeneration. Formulas have been developed as dietary supplements to cater to the high demand from consumers and patients with eye problems. Many of the formulated dietary supplements that are sold in the market have been clinically proven for their efficacy to treat eye diseases. Although the bioactivities in the supplement capsules or tablets have been scientifically established for reducing risks of several diseases, which include macular degeneration and other eye-related diseases, knowledge on the right dosage, efficacy, and bioavailability of antioxidants, vitamins, and minerals is important for consumers. The information may help them make the best decision in choosing the right dietary supplements and nutraceuticals following the evidence-based recommended dosages and reference intakes for improving general health and preventing eye-related diseases. This review covers the potential causal factors involved in eye diseases, clinically proven treatments, and controversial findings on the antioxidants in the prevention of macular degeneration. Future studies should consider multiethnic and multicenter trials for eliminating potential bias in research.Entities:
Keywords: anthocyanin; dietary supplement; lutein; mineral; vitamin; zeaxanthin
Year: 2019 PMID: 30986936 PMCID: PMC6523787 DOI: 10.3390/antiox8040085
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Chemical structures of (A) cyanidin and (B) delphinidin.
Protective effects of anthocyanins and carotenoids against age-related macular degeneration and eye-related complications.
| Compounds | Study Design | Doses | Outcomes | Ref. |
|---|---|---|---|---|
|
| ||||
| Cyanidin 3-glucoside, cyanidin 3-rutinoside, delphinidin 3-glucoside, and delphinidin 3-rutinoside | In vitro bioassays: Rod outer segment and opsin membranes of frog | 10–50 µM | Positive outcomes: Cyanidin 3-glucoside and cyanidin 3-rutinoside stimulated regeneration of rhodopsin | [ |
| Cyanidin 3-glucoside and delphinidin 3-glucoside | Cell culture: ARPE-19 cells (human retinal pigment epithelial cell line) | 5 μM | Positive outcome: Anthocyanins pre-treatment attenuated apoptosis of ARPE-19 cells induced by UVB irradiation. | [ |
| Bilberry anthocyanin extract | In vivo study: Retinal degeneration model in pigmented rabbits (seven days) | 250 and 500 mg/kg/day | Positive outcomes: Attenuated changes caused by light to Bax, Bcl-2, and caspase-3. | [ |
| Anthocyanin supplement | Randomized, parallel study. Postmenopausal, one woman (eight months) | 60 mg/day | Negative outcome (compared to baseline): No significant increase in macular pigment optical density | [ |
|
| ||||
| Lutein and zeaxanthin | Cell culture: ARPE-19 cells | 5 μM | Positive outcome: Anthocyanins pre-treatment attenuated apoptosis of ARPE-19 cells induced by UVB irradiation. | [ |
| Lutein and zeaxanthin | Prospective, randomized, double-blind, placebo-controlled human study (12 months) | 10 mg/day lutein and 2 mg/day zeaxanthin | Positive outcomes: | [ |
| Zeaxanthin-containing spirulina (4–5 g) | Human feeding trials (45 days) | 2.6–3.7 mg zeaxanthin | Positive outcome: Increased mean serum zeaxanthin concentration from 0.06 to 0.15 μmol/L. | [ |
| Lutein, zeaxanthin, and meso-zeaxanthin in sunflower oil suspension | Double-blind, placebo-controlled, block-randomized human trial (12 months) | 10 mg lutein, 10 mg meso-zeaxanthin, and 2 mg zeaxanthin | Positive outcomes: | [ |
| Lutein vs. α-tocopherol | Randomized, double-blind, placebo-controlled supplementation study (24 months) | 12 mg lutein mixtures and 100 mg α-tocopherol | Positive outcomes: | [ |
| Oral total daily supplementation of antioxidants (mixture of β-carotene with other vitamins) | Randomized, placebo-controlled clinical trial (followed up for up to 10 years) | 15 mg β-carotene | Positive primary outcome (compared to baseline): Reduced risk of visual acuity lost. Negative secondary outcomes: No significant differences for all the secondary outcomes between the treatment group and placebo. | [ |
| Nutrient intake (β-carotene, β-cryptoxathin, lutein, zeaxanthin, and lycopene) | Epidemiological study (Self-report data) | - | Positive outcome: Participants with the highest self-reported dietary intake of lutein and zeaxanthin were inversely associated with advancedage-related macular degeneration (AMD). | [ |
| Total carotenoids (lutein/zeaxanthin, α-carotene, β-carotene, cryptoxanthin, and lycopene | Eye Disease Case-Control Study | - | Positive outcome: Serum carotenoid level significantly associated with the risk of AMD | [ |
| Xanthophyll supplement | Randomized, parallel study. Postmenopausal women (8 months) | 6 mg lutein and 2 mg zeaxanthin daily) | Positive outcome: Dietary supplementation of lutein and zeaxanthin significantly increased the serum lutein and zeaxanthin levels. | [ |
Figure 2Chemical structures of (A) lutein, (B) zeaxanthin, and (C) β-carotene.
Positive and negative outcomes of vitamins and minerals against age-related macular degeneration and eye-related complications.
| Compounds | Study Design | Doses | Outcomes | Ref. |
|---|---|---|---|---|
|
| ||||
| Mixture of vitamin C and vitamin E with provitamin A carotenoid | Randomized, placebo-controlled clinical trials (followed-up for up to 10 years) | Vitamin C (500 mg) and vitamin E (400 IU) daily | Positive primary outcomes (compared to baseline): | [ |
| Provitamin A β-carotene, vitamin C, and vitamin E | Age-Related Eye Disease Study | - | Positive outcomes: Increased intake of β-carotene, vitamin C, and vitamin E associated with a reduced risk of neovascular AMD. | [ |
| Vitamin A, vitamin C, and vitamin E | Systematic review and meta-analysis | - | Positive outcomes: Dietary intake of a mixture of vitamin A, vitamin C, and vitamin E had a larger effect on the reduction of AMD risk than the individual vitamin. | [ |
| Vitamin A, vitamin C, and vitamin E | Case-control study | - | Positive outcomes: Low dietary intake of vitamin C and vitamin E was associated with neovascular AMD. | [ |
| Vitamin E | Randomized controlled trial (four years) | 500 IU daily | Negative outcomes: Failed to prevent the development and progression of AMD. | [ |
| Vitamin E | Randomized placebo controlled 4-arm trial (follow-up of 5.6 ± 1.2 years) | 400 IU daily (DL-α-tocopherol acetate) | Negative outcome: Vitamin supplementation showed no protective effect against cataracts among the participants (elderly men). | [ |
| Vitamin A, vitamin C, and vitamin E | Multicenter eye disease case-control study (Epidemiological study) | - | Negative outcomes: Vitamins A, C, and E consumptions were not associated with the reduced risk of AMD. | [ |
| Vitamin A (retinol), vitamin C (ascorbic acid), and vitamin E (α-tocopherol) | POLA (Pathologies Oculaires Liées à l’Age) study | - | Negative outcomes: | [ |
| Vitamin C | Cochrane Review | - | Negative outcomes: Vitamin C supplementation did not prevent any AMD or late AMD. | [ |
| Vitamin C and vitamin E | Eye Disease Case-Control Study | - | Negative outcome: No statistically significant overall association was found between serum vitamin status and neovascular AMD. | [ |
|
| ||||
| Zinc | Case-control study | - | Positive outcome: Low dietary intake of zinc was associated with neovascular AMD. | [ |
| Zinc | Randomized, placebo-controlled clinical trials (followed-up for up to 10 years) | Zinc oxide (80 mg daily) | Positive outcome: Significantly reduced the risk of developing advanced AMD. | [ |
| Zinc | Randomized double-blinded, placebo-controlled trials (2 years intervention) | Zinc sulfate (200 mg daily) | Positive outcome: Significantly reduced visual loss in treatment group compared to placebo. | [ |
| Zinc | Randomized, prospective, placebo-controlled clinical trial (three and six months intervention) | Zinc monocysteine (25 mg daily) | Positive outcomes: | [ |
| Zinc | Randomized, double-blinded, placebo-controlled study (two years intervention) | Zinc sulfate (200 mg daily) | Positive outcome: Significantly increased serum zinc. | [ |
| Selenium | Randomized, placebo-controlled, 4-arm trial (follow-up of 5.6 ± 1.2 years) | 200 μg daily (from | Negative outcome: Selenium supplementation did not show significant effect in reducing risk of cataracts among the participants (elderly men). | [ |
Recommended daily intakes and tolerable upper intake level (UL) for vitamins and minerals [88].
| Nutrients | Recommended Daily Intake | UL |
|---|---|---|
|
| ||
| Vitamin A | 700 μg RE/day for men and 600 μg RE/day for women | 3000 μg RE/day |
| Vitamin C | <1000 mg/day | 1000 mg/day |
| Vitamin E | 300 mg α-tocopherol equivalents (450 IU) | 300 mg α-tocopherol equivalents (450 IU) |
|
| ||
| Selenium | 26–55 µg/day | 300 μg/day |
| Zinc | 11 mg/day for men and 8 mg/day for women | 25 mg/day |